P
Patricia Massicotte
Researcher at University of Alberta
Publications - 42
Citations - 3302
Patricia Massicotte is an academic researcher from University of Alberta. The author has contributed to research in topics: Thrombosis & Low molecular weight heparin. The author has an hindex of 26, co-authored 42 publications receiving 2939 citations. Previous affiliations of Patricia Massicotte include Boston Children's Hospital & McMaster University.
Papers
More filters
Journal ArticleDOI
Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Paul Monagle,Elizabeth Chalmers,Anthony K.C. Chan,Gabrielle deVeber,Fenella J. Kirkham,Patricia Massicotte,Alan D. Michelson +6 more
TL;DR: Within this chapter, the majority of recommendations are separate for neonates and children, reflecting the significant differences in epidemiology of thrombosis and safety and efficacy of therapy in these two populations.
Journal ArticleDOI
Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association
Donna M. Ferriero,Heather J. Fullerton,Timothy J. Bernard,Lori Billinghurst,Stephen R. Daniels,Michael R. DeBaun,Gabrielle deVeber,Rebecca Ichord,Lori C. Jordan,Patricia Massicotte,Jennifer Meldau,E. Steve Roach,Edward R. Smith +12 more
TL;DR: In this paper, the authors presented a synthesis of data and a consensus of the leading experts in childhood cardiovascular disease and stroke, including arterial ischemic, venous thrombotic, and hemorrhagic stroke.
Journal ArticleDOI
An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial.
Patricia Massicotte,Jim A. Julian,Michael Gent,Karen Shields,Velma Marzinotto,Barbara Szechtman,Anthony K.C. Chan,Maureen Andrew +7 more
TL;DR: The use of reviparin-sodium for short-term prophylaxis of CVL-related VTE in children was safe but its efficacy remains unclear, and although underpowered, PROTEKT provided valuable information on event rates and predictors ofCVL- related VTE.
Journal ArticleDOI
A cross-sectional study evaluating post-thrombotic syndrome in children☆
Stefan Kuhle,Barbara Koloshuk,Velma Marzinotto,Mary E. Bauman,Patricia Massicotte,Maureen Andrew,Anthony K.C. Chan,Mohamed Abdolell,Mohamed Abdolell,Lesley Mitchell +9 more
TL;DR: It is demonstrated that PTS is a clinically significant disease in children with previous DVT and risk factors for development of PTS were identified.
Journal ArticleDOI
An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.
Patricia Massicotte,Jim A. Julian,Michael Gent,Karen Shields,Velma Marzinotto,Barbara Szechtman,Maureen Andrew +6 more
TL;DR: Although limited by small sample size, REVIVE provides valuable information on the incidence of recurrent VTE, major bleeding and problematic issues associated with therapy of VTE in children.